Rationale: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk of death and drive healthcare costs, but whether they accelerate loss of lung function remains controversial. Whether exacerbations in subjects with mild COPD or similar acute respiratory events in smokers without airflow obstruction affect lung function decline is unknown.
Objectives: To determine the association between acute exacerbations of COPD (and acute respiratory events in smokers without COPD) and the change in lung function over 5 years of follow-up.
Methods: We examined data on the first 2,000 subjects who returned for a second COPDGene visit 5 years after enrollment. Baseline data included demographics, smoking history, and computed tomography emphysema. We defined exacerbations (and acute respiratory events in those without established COPD) as acute respiratory symptoms requiring either antibiotics or systemic steroids, and severe events by the need for hospitalization. Throughout the 5-year follow-up period, we collected self-reported acute respiratory event data at 6-month intervals. We used linear mixed models to fit FEV 1 decline based on reported exacerbations or acute respiratory events.
Measurements and Main Results:
In subjects with COPD, exacerbations were associated with excess FEV 1 decline, with the greatest effect in Global Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbation was associated with an additional 23 ml/yr decline (95% confidence interval, 2-44; P = 0.03), and each severe exacerbation with an additional 87 ml/yr decline (95% confidence interval, 23-151; P = 0.008); statistically significant but smaller effects were observed in Global Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects. In subjects without airflow obstruction, acute respiratory events were not associated with additional FEV 1 decline.
Conclusions: Exacerbations are associated with accelerated lung function loss in subjects with established COPD, particularly those with mild disease. Trials are needed to test existing and novel therapies in subjects with early/mild COPD to potentially reduce the risk of progressing to more advanced lung disease.
Acute exacerbations of chronic obstructive pulmonary disease (COPD) account for most COPD-related costs (1) and when frequent lead to marked reductions in health-related quality of life (2) . Severe exacerbations requiring hospitalization also portend a poor prognosis, with 1-and 5-year mortality exceeding 20% and 50% (3) (4) (5) (6) . Although these impacts have been consistently reported, whether acute exacerbations impact the rate of decline of lung function over time remains uncertain. Although many COPD treatments reduce exacerbation frequency and some studies suggest that inhaled therapies may reduce FEV 1 decline (7, 8) , there is no information about the association between these two key disease features. Many smokers without COPD also suffer acute respiratory events that appear clinically similar to classic exacerbations in those with established COPD (9, 10) . Whether such respiratory events accelerate lung function loss or lead to the development of COPD is unknown.
Previous studies have examined the relationship between acute respiratory illnesses and lung function decline in subjects with established COPD but the findings are not consistent (11) (12) (13) (14) (15) (16) (17) (18) . Although some have suggested a significant excess loss of FEV 1 for each respiratory event (13) , or in those with frequent events (15) , others have reported minimal (12) or no relationship (18) . Such disparate results may result from design differences including sample size, study duration, and exacerbation definitions. Most previous studies also focused on more advanced COPD; only the Lung Health Study included subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 COPD (FEV 1 .80% of predicted) and none included those without airflow obstruction (GOLD stage 0) or with a nonspecific or restrictive type spirometric pattern (preserved ratio impaired spirometry [PRISm] ) (19, 20) . Although the GOLD guidelines include prevention of exacerbations as a major treatment goal in patients with established COPD (3), there are uncertainties about the link between exacerbations and lung function loss, particularly in patients with mild airflow obstruction (21) .
The COPDGene (Genetic Epidemiology of COPD) study enrolled current and former smokers and obtained spirometry and detailed respiratory illness history at the time of enrollment and captured exacerbations in longitudinal follow-up assessments over 5 years (22) . The study provides a robust dataset to further understand how respiratory events relate to longitudinal FEV 1 decline across a wide range of COPD severity and in smokers without COPD. We hypothesized that acute respiratory events would be associated with more rapid FEV 1 decline in all GOLD stages.
Methods

Study Population and Assessments
COPDGene (NCT00608764) is a multicenter longitudinal observational cohort study that initially enrolled 10,300 participants (22) . Subjects in the current analysis were the first 2,000 subjects who returned for a second COPDGene visit approximately 5 years after their initial visit. To minimize bias related to missing data, we also included baseline data for the 861 subjects who were more than 1 year late for their return visit or declined further participation sometime after their first visit. Written informed consent was obtained from subjects, and the study was approved by the institutional review boards of all 21 participating centers.
COPDGene participants were nonHispanic white and African American current and former smokers with at least a 10 pack-year smoking history, with and without COPD (22) . We excluded subjects with known lung diseases other than asthma, such as lung cancer, bronchiectasis, and interstitial lung disease. At baseline and at 5 years after the initial visit, spirometry was performed (Easy-One spirometer; NDD, Andover, MA) before and after administration of 180 mg of albuterol (via Aerochamber Activis, Parsippany, NJ). Bronchodilator reversibility was defined as at least 12% and 200-ml increase in FEV 1 or FVC post-bronchodilator (23) . COPD severity was assessed using spirometry criteria outlined by the GOLD guidelines with reference values from the National Health and Nutrition Examination Survey III (24, 25) . GOLD stage 0 refers to current and former smokers without COPD, which although not included in the current GOLD guidelines, was used previously (26) . Subjects with PRISm are current and former smokers with reduced FEV 1 less than 80% predicted but normal FEV 1 /FVC ratio (.0.70) (19) .
At baseline and follow-up, we performed high-resolution computed tomographic scans at full inspiration. Emphysema was estimated by the percentage of lung volume on the inspiratory computed tomographic with attenuation less than 2950 HU (low-attenuation area, %LAA950insp) using 3D Slicer software (www.airwayinspector.org) (22) .
Exacerbations (and acute respiratory events in those without established COPD) were defined as acute respiratory symptoms that required use of either antibiotics or systemic steroids; severe events were defined by the need for hospitalization (3). Selfreported acute respiratory event data were collected at 6-month intervals, via an automated telephony system, web-based survey, or telephone contact throughout the follow-up period between visits 1 and 2 (27) .
Statistical Analyses
Linear mixed models were used to fit FEV 1 longitudinally, stratified by GOLD group. Primary predictors included visit (baseline and follow-up), acute respiratory events/ exacerbations, and their interaction. Covariates included baseline race, sex, percent emphysema, and smoking status (continuing, intermittent, or former based on longitudinal follow-up data) as ORIGINAL ARTICLE time-invariant variables; and weight, age, height, and bronchodilator response as time-varying variables. Squared terms for age and height were also included in the models. An unstructured covariance structure was used for repeated measures. Total number of exacerbations, number of severe exacerbations, and binary categorization of exacerbations (none vs. at least one) were used as predictors in separate models. Data from subjects that either completed both visits (completers) or only completed visit 1 and were either overdue by at least 1 year or requested no further contact (late) were used to fit models. Subjects with visit 1 data but who died before visit 2 (deceased) were not included in primary analyses. For more details, see the online supplement. All statistical analyses were performed in SAS 9.4 (Cary, NC).
Results
For subjects completing both visits, the average time between visit 1 and visit 2 was 5.25 years. Clinical characteristics of the primary analytic cohort are shown in Table 1 . Subjects in the PRISm and GOLD stage 0 groups were slightly younger at their baseline visit than those with established airflow obstruction, were more often female and African American, and exhibited less bronchodilator responsiveness. Current smoking rates declined with increasing severity of COPD, whereas the extent of emphysema and use of inhaled medications was greater in those with more airflow obstruction. As previously published, the use of inhaled medications was as or more common in PRISm subjects than in those with GOLD stage 0/1 disease (20) .
Of the initial 10,300 enrolled subjects, 3,521 were due for visit 2 at the time of analysis. Of these, 2,000 subjects were in the completer subgroup. There were 861 and 660 in the late and deceased subgroups, respectively. Subgroups were generally similar except for more former smokers among the completers in PRISm and GOLD stage 0-1 groups compared with late and deceased, and lower baseline mean FEV 1 in GOLD stage 2-4 for deceased compared with completers in GOLD stage 2-4 (see Table E1 in the online supplement). The proportion of late subjects was similar across GOLD groups (20% for GOLD stage 4 and 23-26% for all other GOLD groups including PRISm). The number of deaths in the GOLD stage 0 through stage 4 groups were 115 (9%), 27 (10%), 127 (18%), 151 (30%), and 174 (57%), respectively, and 66 (17%) for PRISm subjects.
Analysis of the exacerbation/acute respiratory event frequency showed that exacerbations were common in all groups ( Table 2) , with more than a third (36.7%) of subjects reporting events during follow-up. Both the proportion of subjects who suffered any event and the annualized rates increased with worsening lung function. Severe events requiring hospitalization were common, even in the PRISm and GOLD stage 0 groups (at least once during followup in 14% of PRISm, and 8% of GOLD stage 0), although such events increased markedly in more advanced COPD (at least once during follow-up in 10% of GOLD stage 1, 24% of GOLD stage 2, 42% of GOLD stage 3, and 47% of GOLD stage 4).
Among subjects without exacerbations/ acute respiratory events, we found rates of FEV 1 change between 15 and 225 ml/yr Exacerbations/acute respiratory events of any severity were associated with statistically significant excess FEV 1 decline in GOLD stage 1, 2, and 3 subjects. The magnitude of effect was largest in GOLD stage 1 subjects, where each exacerbation was associated with an additional 23 ml/yr decline in FEV 1 . We also found that severe exacerbations were associated with greater declines in FEV 1 and again the strongest effects were seen in GOLD stage 1 subjects, where each severe exacerbation was associated with an additional 87 ml/yr decline in FEV 1 (Table 3, Figure 1 ). There was no statistically significant excess decline in FEV 1 for each additional exacerbation/acute respiratory event of any severity in any of the PRISm, GOLD stage 0, or GOLD stage 4 groups, although the GOLD stage 4 data may be impacted by survivor bias as discussed later. Our primary model used completers and visit 1 data for late subjects; additional models were fit for completers only (see online supplement) and for completers and visit 1 data for late and deceased subjects combined (data not shown) and yielded similar results.
As expected, we found a steeper average decline in FEV 1 among current and Definition of abbreviations: CI = confidence interval; GOLD = Global Initiative for Chronic Obstructive Lung Disease; PRISm = preserved ratio impaired spirometry.
Estimates reflect average changes after factoring out expected changes caused by time-varying covariates (age, height, weight, and bronchodilator responsiveness). For example, the change in FEV 1 for a GOLD stage 1 subject with one, two, or three exacerbations over the follow-up period can be estimated by adding the excess decline per exacerbation event (223 ml/yr) to the rate in those without events (225 ml/yr), yielding a final annual rate of 248 ml/yr, 271 ml/yr, and 294 ml/yr. Number of subjects available for analysis for PRISm, GOLD 0, GOLD 1, GOLD 2, GOLD 3, and GOLD 4 groups were 267, 1,055, 227, 515, 320, and 113, respectively; number of records available for analysis for the respective groups were 481, 1,891, 404, 913, 543, and 183. Some records were not usable because of missing data for bronchodilator responsiveness, emphysema rate, exacerbations, or some combination of these (see Table 1 and online supplement for more details).
intermittent smokers (9-ml decline) than among former smokers (2-ml decline; P = 0.005 for difference). Because smoking cessation slows the rate of FEV 1 decline, we extended models by including smoking status as an effect modifier; models included up to three-way interaction terms with time, occurrence of severe exacerbations (defined as none vs. at least one), and smoking status (former vs. current or intermittent). For GOLD stage 2 and 3 subjects there was a steeper decline in FEV 1 over time for current/intermittent smokers with a severe acute exacerbation versus subjects that were either former smokers or did not suffer a severe acute exacerbation or both (57 ml/yr vs. 18 ml/yr; P , 0.0001 for GOLD stage 2; 39 ml/yr vs. 10 ml/yr; P = 0.008 for GOLD stage 3). Similar results were found when considering exacerbations of any type.
Discussion
The results of this study of more than 2,000 well-characterized current and formers smokers followed for 5 years demonstrate that acute exacerbations are associated with accelerated declines in FEV 1 in those with established COPD, particularly in those with mild (GOLD stage 1) disease and when the exacerbations are severe. By contrast, although many current and former smokers without airflow obstruction have respiratory impairment and suffer exacerbation-like respiratory events (9, 10), we found no evidence that these accelerate lung function loss. Collectively, these findings support the hypothesis that acute exacerbations contribute to COPD progression, particularly in those with disease that is initially mild. These findings provide novel information in the long-standing debate about the role of bronchitic episodes in the pathogenesis of COPD associated with tobacco products. In the 1970s, the original West London longitudinal spirometry study by Fletcher and Peto (11) demonstrated no relationship between bronchial infections and rate of decline in FEV 1 . By contrast, a contemporaneous cohort in the United States did find a relationship between lower respiratory illness frequency and FEV 1 decline among 150 subjects who had COPD at entry (14) . Subsequent longitudinal analysis from the Lung Health Study suggested that in continuous and intermittent smokers, each lower respiratory infection reported was associated with an additional 7 ml/yr decline in FEV 1 , although no effect was seen in those who had quit smoking (13). Donaldson and colleagues (15) found a similar estimate of additional lung function loss (8 ml/yr) in subjects with frequent exacerbations (defined as .2.92 exacerbations/yr) as compared with those without, although the study was small (n = 109) and the exacerbations were based on diary records and thus mild in many cases.
Contradictory data came from the 3-year ECLIPSE study, which reported only a 2 ml/yr greater annual decline in FEV 1 per exacerbation (although no GOLD stage 1 subjects were included) (12) , whereas the 5-year Hokkaido COPD cohort study found no relationship between exacerbations and FEV 1 decline, although the population enrolled was also quite small (n = 268) (18) . Our analysis confirms a relationship between exacerbations and lung function loss in subjects with GOLD stage 2 and 3 disease and adds convincing data that the effect is greatest in subjects with more mild COPD (GOLD stage 1) and for more severe events.
Our observation that lung function loss related to exacerbations was greatest in those with GOLD stage 1 disease is novel and has several potential implications for COPD care. First is the possibility that preventing exacerbations in this subpopulation could reduce the risk of developing severe COPD, an important hypothesis that should motivate randomized trials. The possibility that mildto-moderate disease may be more amenable to therapy than severe airflow obstruction is supported by the UPLIFT study, which suggested that exacerbations, mortality, and perhaps FEV 1 decline were all reduced by tiotropium in subjects with FEV 1 greater than 60% (28) . The link between exacerbations and lung function decline has been questioned, in part because many drugs reduce the risk of exacerbation but none have been definitively shown to reduce FEV 1 loss. This could be explained by the fact that earlier studies mostly excluded GOLD stage 1 COPD.
An unanticipated finding was the lack of evidence that acute respiratory events impact lung function loss in subjects with GOLD stage 0 disease or PRISm. Both of these groups have been demonstrated to have significant respiratory symptoms and impairment, in some cases greater than subjects with GOLD stage 1 COPD, and as we observed, they are also often treated with long-acting bronchodilators and inhaled corticosteroids despite no evidence to support that practice (9, 10, 19, 29) . We can only speculate about why no relationships between acute respiratory events and FEV 1 decline were observed in these subjects. One possibility is that whatever mechanisms protect them from the development of COPD, such as enhanced antiinflammatory or reparative capacity, also protect against lung function loss with episodes of bronchitis. A second possibility that requires additional testing is that acute respiratory events in GOLD stage 0 subjects are fundamentally different from those in subjects with established COPD, a possibility supported by the observation that patients with COPD but not healthy smokers had significant increases in bacterial colonization after experimental respiratory rhinoviral infection (30) . As shown in COPDGene (9) , and recently confirmed in the SPIROMICS (Subpopulations and InteRmediate Outcome Measures In COPD Study) cohort (29) , the risk of acute respiratory events in symptomatic GOLD 0 current and former smokers often exceeds the risk in patients with established COPD. Additional followup of SPIROMICS participants should allow further analyses to either confirm or refute our findings. PRISm subjects have increased emphysema and airway wall thickness, relative to smokers with normal spirometry, but have several distinct features compared with those with typical COPD including less bronchodilator responsiveness and greater body mass index (19) . PRISm has also proven to be heterogeneous with several phenotypic clusters, each likely the result of different pathophysiologic processes (20) . This diversity also likely impacts the nature and impact of acute respiratory events in different PRISm subjects and requires further study.
Although our study was not designed to confirm the pathophysiologic link between exacerbations, their severity, and lung function decline, and we cannot assign directional causality, several plausible mechanisms could be proposed. First, exacerbations are associated with significant pulmonary inflammation including activation of matrix metalloproteinases (31) and increased hyaluronidase activity (32) , which may trigger a number of permanent changes to the lung parenchyma including airway fibrosis and additional loss of alveolar tissue. Second, some subjects who suffer prolonged exacerbations may not fully recover before the next episode begins leading to a progressive deterioration with each event and faster lung function loss over time (33) . Greater increases in sputum IL-8 and IL-6 from baseline to Day 7 of an exacerbation predict a delayed recovery, potentially linking severe exacerbations to more pronounced inflammation and larger lung function decline (34) .
Strengths of our study include its large, multicenter sample, longitudinal study design, use of standardized postbronchodilator spirometry, our careful collection of exacerbation data over a 5-year period, and the inclusion of large numbers of GOLD stage 0 and PRISm subjects. The study is limited by the loss of some subjects to follow-up, and because it was observational in nature, we cannot assign causality between exacerbations and loss of lung function. Missing data poses issues with many longitudinal studies, and we attempted to account for potential bias in estimates caused by missing data and understand differences between completers and Dropouts by examining their baseline characteristics. We did find completers, late, and deceased subjects to be fairly similar in regards to demographic characteristics and baseline lung function. In addition, our primary analytical approach allowed FEV 1 decline estimates to be adjusted based on visit 1 data for subjects who were late for visit 2.
Still, there is the potential that data were missing not at random. In particular, it is possible that late subjects had a faster decline in FEV 1 than completers, and we have no information about progression in the former group because there were only two visits requiring spirometry (see online supplement for further discussion.) We do not consider subjects that had COPDrelated deaths before they could complete visit 2 as having missing data, but rather, as having an alternative outcome to an FEV 1 measurement (although subjects that died before visit 2 may also have had a steeper average FEV 1 decline after visit 1 than completers). It is therefore important to consider overall survival and FEV 1 decline for living subjects to portray a more complete picture of disease progression and note that although the declines in FEV 1 diminished with increasing GOLD stage (and were in fact not significant in GOLD stage 4), survival also decreased. Although information on final cause of death was unavailable, we anticipate many were directly or indirectly related to COPD.
Our study is also limited by the collection of spirometry at only two time points, approximately 5 years apart. Although analyses of FEV 1 decline has traditionally relied on more frequent collection of data, we note that in the Lung Health Study, the slopes of FEV 1 decline estimated over five annual tests was not different from that measured with only two time points 6 years apart (35) . In addition, we did not collect data about how exacerbations were treated (antibiotics, systemic corticosteroids, or both) and thus cannot compare the relative impact of exacerbation treatment on lung function loss.
In summary, we provide novel evidence that exacerbations accelerate lung function loss in subjects with established COPD, particularly when these events are severe and occur in those with mild disease. These findings emphasize the need for clinical trials in early/mild COPD, to test whether preventing exacerbations could reduce progression to more advanced lung disease. n
